SageView Advisory Group’s Inhibrx INBX Stock Holding History

SageView Advisory Group’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28	Closed	-$2.21K	–	1459
2025 Q4	$2.21K	Buy	+28	New	+$1.91K	﹤0.01%	2215

Other funds holding INBX

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

SageView Advisory Group's INBX Position: Q1 2026 in Review

SageView Advisory Group sold out of Inhibrx (INBX) in Q1 2026, closing a stake of 28 shares — an estimated $2.21K sold.

SageView Advisory Group first reported a position in INBX in Q4 2025 and held it in 1 quarter. The position peaked at $2.21K in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

SageView Advisory Group reported no remaining Inhibrx position as of Q1 2026 after selling out during the quarter.
SageView Advisory Group sold 28 Inhibrx shares in Q1 2026, an estimated $2.21K.
SageView Advisory Group first reported a position in Inhibrx in Q4 2025 and held it in 1 quarter.
SageView Advisory Group's Inhibrx position peaked at $2.21K in Q4 2025.
135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.